Medical Data Vision Co.Ltd. (3902) AI Stock Analysis

• Market Cap: ¥65.83B
• Dividend Yield: 0.39%
• Average Volume (3M): 221.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.10
• Revenue Growth: 6.17%
• EPS Growth: -8918.66%
• Country: JP
• Employees: 315
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 1.73
• Shares Outstanding: 40,027,527
• 10 Day Avg. Volume: 317,960
• 30 Day Avg. Volume: 221,940
• PEG Ratio: 0.10
• Price to Book (P/B): 4.84
• Price to Sales (P/S): 2.54
• P/FCF Ratio: -14.53
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: ¥1,681.00 ▼(-0.41% Downside)

The score is held down primarily by the 2024 fundamental deterioration (losses and negative cash flow) and weak valuation signals from a negative P/E. Technicals are supportive due to strong upward trend and momentum, but extremely overbought readings increase downside risk and limit the boost to the overall score.

Positive Factors

Market Position

The company's improved financial performance and net income growth indicate a strengthened market position, enhancing its competitive edge in the healthcare data sector.

Operational Efficiency

The shift from a loss to net income suggests enhanced operational efficiency, which can lead to sustainable profitability and improved shareholder value.

Balance Sheet Health

A debt-free balance sheet reduces financial risk and provides flexibility for future investments, supporting long-term stability.

Negative Factors

Revenue Decline

The decline in revenue and profitability in 2024 indicates potential challenges in maintaining growth, impacting long-term financial health.

Cash Flow Weakness

Negative cash flow raises concerns about the company's ability to fund operations and growth initiatives, posing risks to financial stability.

Forecast Revisions

Revised forecasts due to sales delays suggest potential execution risks and may impact investor confidence and future growth prospects.

Medical Data Vision Co.Ltd. Business Overview & Revenue Model

Company Description

Medical Data Vision Co., Ltd. develops, produces, maintains, and sells medical information integration systems in Japan. The company also offers medical data analysis, survey, and consulting services; management consulting services for medical institutions; and medical data services, as well as plans, designs, develops, and operates portal sites. It provides its services to pharmaceutical companies, medical device manufacturer, academia, research institution, and health insurance providers. The company was founded in 2003 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Medical Data Vision Co., Ltd. makes money primarily through the sale and subscription of its healthcare IT solutions. The company's key revenue streams include licensing fees for its software products, subscription fees for its cloud-based services, and consulting fees for implementation and support services. Additionally, the company may generate income from partnerships with other healthcare technology firms and institutions, as well as from providing data analytics services to healthcare providers looking to optimize their operations and improve patient outcomes.

Medical Data Vision Co.Ltd. Financial Statement Overview

Summary

Medical Data Vision Co. Ltd. faces financial headwinds, with declining revenues and profitability impacting its income statement. While the balance sheet shows resilience due to no leverage, the negative cash flow trends highlight potential liquidity concerns. The company should focus on improving operational efficiency and cash flow management to enhance its financial health.

Income Statement

The company experienced a significant decline in revenue and profitability. The gross profit margin decreased from previous years, and the net profit margin turned negative in 2024, indicating profitability challenges. The EBIT and EBITDA margins also showed substantial deterioration, reflecting operational inefficiencies and financial strain.

Balance Sheet

The balance sheet remains strong with no debt, suggesting financial stability. The equity ratio is solid, indicating a high proportion of assets are funded by equity. However, the decline in stockholders' equity and total assets in 2024 suggests a reduction in financial resources.

Cash Flow

Cash flow metrics reveal significant issues, particularly with negative operating cash flow and free cash flow in 2024. The free cash flow to net income ratio has deteriorated, indicating cash flow constraints. This poses risks to the company's financial flexibility and ability to fund operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.16B	5.91B	6.42B	6.10B	5.67B	4.58B
Gross Profit	4.40B	4.33B	5.03B	5.03B	4.64B	3.88B
EBITDA	88.91M	130.00M	1.87B	1.91B	1.73B	1.31B
Net Income	-715.18M	-791.17M	979.13M	870.51M	1.09B	700.22M
Balance Sheet
Total Assets	4.63B	4.75B	6.23B	4.90B	5.53B	5.32B
Cash, Cash Equivalents and Short-Term Investments	1.83B	1.35B	3.22B	2.26B	3.22B	3.19B
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	1.80B	1.59B	1.91B	1.29B	1.33B	1.18B
Stockholders Equity	2.80B	3.10B	4.25B	3.52B	4.16B	4.10B
Cash Flow
Free Cash Flow	0.00	-1.03B	1.59B	857.55M	1.06B	937.32M
Operating Cash Flow	0.00	-877.85M	1.62B	910.79M	1.08B	964.37M
Investing Cash Flow	0.00	-592.97M	-437.83M	-868.75M	-26.93M	-142.58M
Financing Cash Flow	0.00	-399.00M	-225.26M	-979.36M	-1.03B	-589.64M

Medical Data Vision Co.Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1688.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Negative
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3902, the sentiment is Positive. The current price of 1688 is above the 20-day moving average (MA) of 1603.05, above the 50-day MA of 921.28, and above the 200-day MA of 581.13, indicating a bullish trend. The MACD of 235.65 indicates Positive momentum. The RSI at 95.65 is Negative, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3902.

Medical Data Vision Co.Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3649	79 Outperform	¥24.46B	20.55	―	1.75%	-2.05%	-9.92%
3939	76 Outperform	¥25.09B	22.59	―	1.39%	9.85%	20.83%
4320	74 Outperform	¥17.97B	10.80	―	4.99%	8.77%	1078.88%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
3902	49 Neutral	¥65.83B	-152.64	―	0.39%	6.17%	-8918.66%

Medical Data Vision Co.Ltd. Corporate Events

Medical Data Vision Reports Strong Financial Turnaround for 2025

Medical Data Vision Co., Ltd. reported a significant turnaround in its financial performance for the nine months ending September 30, 2025, with net sales increasing by 12.7% year-on-year to 4,650 million yen. The company achieved a net income of 55 million yen, a notable improvement from the previous year’s loss. This positive financial performance reflects the company’s strengthened market position and operational efficiency, potentially impacting stakeholders positively by enhancing shareholder value and market confidence.

Medical Data Vision Revises 2025 Financial Forecasts Amid Sales Delays

Medical Data Vision has revised its financial forecasts for the fiscal year ending December 31, 2025, due to lower-than-expected net sales and profits. Despite achieving record sales in the first half of the year, delays in the installation of the ‘ALPHA ･SALUS’ system and a careful examination of prospective projects have led to a significant downward revision. The company continues to invest in future growth, particularly by expanding its sales personnel, but expects operating income, ordinary income, and net income to be considerably lower than initially projected.